Welcome to our dedicated page for Spectral AI news (Ticker: MDAI), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.
Spectral AI, Inc. (Nasdaq: MDAI) is a predictive AI company in the healthcare sector developing the DeepView® System for medical diagnostics in wound care, with a primary focus on burns. The news flow around Spectral AI centers on the progress of its DeepView technology, regulatory milestones, clinical evidence, and financing activities that support ongoing development.
Company news frequently includes updates on regulatory submissions and interactions, such as the announced submission of a De Novo 510(k) marketing clearance application to the U.S. Food and Drug Administration for the DeepView System intended for burn care settings. Spectral AI also issues quarterly financial results that discuss research and development revenue, gross margin trends, operating expenses, and the impact of its BARDA Project BioShield contract on reported figures.
Another recurring theme in MDAI news is the company’s participation in professional burn conferences and scientific meetings. Releases describe multiple presentations and posters featuring the DeepView System at events such as the British Burn Association conference, the European Burns Association Congress, and U.S. regional burn conferences. These items highlight clinical studies, reader studies, and early experiences with DeepView in burn centers in the United Kingdom, the United States, and other regions.
Investors and healthcare professionals following MDAI news can also expect announcements on capital raises, including securities purchase agreements, private placements of warrants and pre-funded warrants, and debt facilities that provide growth capital for further development and potential commercialization. Scheduling notices for earnings calls and webcasts appear alongside these updates, offering additional context on the company’s strategy and operational progress.
For users tracking MDAI, this news page provides a focused view of Spectral AI’s ongoing work to advance AI-driven burn wound diagnostics, its financial position, and its engagement with the global burn care community.
Spectral AI (Nasdaq: MDAI) appointed Vincent S. Capone as Chief Executive Officer effective February 9, 2026, promoting its CFO and general counsel as the company shifts toward commercialization of its DeepView® non-invasive, AI-driven burn wound assessment device.
The company highlighted its June 2025 FDA submission as a major milestone and said the leadership change will support commercial execution with the chairman remaining as executive chairman.
Spectral AI (Nasdaq: MDAI) will participate in National Burn Awareness Week, Feb 1–7, 2026, partnering with the American Burn Association to promote workplace burn prevention and employee education.
The company highlighted internal events, leadership messages, engineer stories, and burn-safety tips, and referenced its June 2025 De Novo submission to the FDA for the DeepView System.
Spectral AI (Nasdaq: MDAI) showcased its DeepView System at the Southern Region Burn Conference in Charleston (Oct 30–Nov 2, 2025) and will be highlighted at the Northeast Region Burn Conference in Washington, DC (Nov 21–22, 2025).
The DeepView System was featured in sessions on initial cost savings, AI training methodology, and clinician decision accuracy under a “wait-and-see” approach. Company leaders and clinicians emphasized evidence-based burn assessment and physician collaboration to improve patient outcomes and introduce the technology to the market.
Spectral AI (NASDAQ: MDAI) reported third-quarter 2025 results for the period ended September 30, 2025, highlighting Q3 R&D revenue of $3.8 million and YTD revenue of $15.6 million. Cash improved to $10.5 million as of Sept 30, 2025 (flat vs Q2 2025; up from $3.7M in Q3 2024). The company recorded a Q3 net loss of $3.6 million versus $1.5 million a year earlier, driven by a 54% decline in R&D revenue after its June De Novo submission to the FDA.
After quarter close (Oct 22, 2025) Spectral entered a securities purchase agreement raising ~$7.6 million gross via common shares, warrants and pre-funded warrants. Full-year revenue guidance was lowered from $21.5M to $18.5M, citing BARDA timing and a U.S. government shutdown impact.
Spectral AI (Nasdaq: MDAI) will report third quarter financial results for the period ended September 30, 2025 on Tuesday, November 11, 2025 after market close. The company will host a conference call the same day at 5:00 PM ET to discuss results. Investors can join by dialing 833-630-1956 (U.S.) or 412-317-1837 (International), or via a simultaneous webcast available on the company’s Investor Relations Events & Presentations page at https://investors.spectral-ai.com/news-events/events.
Spectral AI (Nasdaq: MDAI) priced a $7.6 million offering on October 23, 2025 to fund expansion of its DeepView® System. The financing includes the issuance of 4,000,000 shares of common stock and pre-funded warrants at $1.90 per share, plus corresponding warrants with an exercise price of $2.51 per share.
The company said proceeds will support continued development, broaden clinical indications, and prepare for commercial readiness in 2026, while maintaining support for its BARDA Project BioShield contract. Northland Capital Markets served as exclusive placement agent and Reed Smith served as counsel.
Spectral AI (Nasdaq: MDAI), a medical diagnostics company specializing in AI-powered wound care solutions, has been recognized on TIME's World's Top HealthTech Companies 2025 list. The prestigious ranking, published on September 18, 2025, features 400 leading healthcare technology innovators selected from thousands of companies globally.
Companies were evaluated based on three key criteria: financial performance, reputation analysis, and online engagement. The recognition highlights Spectral AI's progress in developing their DeepView technology as they work towards global commercialization of their AI-based predictive wound care solutions.
Spectral AI (NASDAQ: MDAI) showcased its DeepView® System at the European Burns Association (EBA) Congress in Berlin, Germany. The AI-powered medical diagnostics technology was featured in six key presentations and posters from various international medical institutions, primarily focusing on burn wound assessment and treatment.
Notable presentations included studies from the North Bristol NHS Trust, Louisiana State University, and the Royal Victoria Infirmary, demonstrating the system's application in real-world settings. The research highlighted DeepView's capabilities in burn depth assessment, wound healing potential prediction, and patient experience measurements using AI-enhanced multispectral imaging.
Spectral AI (NASDAQ:MDAI), an AI medical diagnostics company focused on wound care, reported its Q2 2025 financial results. The company achieved $5.1 million in R&D revenue for Q2 and $11.8 million for H1 2025. A significant milestone was reached with the completion of their De Novo FDA application submission for the DeepView System in June 2025.
Financial highlights include a cash position of $10.5 million, up from $5.2 million in December 2024, supported by a $15 million debt financing agreement with Avenue Capital Group. The company reported a Q2 net loss of $7.9 million, primarily due to warrant liability adjustments. Gross margin was 45.2%, slightly down from 46.6% in Q2 2024. Management reaffirmed full-year 2025 revenue guidance of $21.5 million.
Spectral AI (NASDAQ: MDAI), a company specializing in AI-driven medical diagnostics for wound care through their DeepView® System, has scheduled its Q2 2025 financial results announcement for August 12, 2025 after market close.
The company will host a conference call at 5:00 PM ET on the same day to discuss the results. Investors can participate by dialing 833-630-1956 (U.S.) or 412-317-1837 (International). A simultaneous webcast will be available on the company's investor relations website.
FAQ
What is the current stock price of Spectral AI (MDAI)?
What is the market cap of Spectral AI (MDAI)?
